Alnylam Pharmaceuticals (ALNY)
(Delayed Data from NSDQ)
$152.29 USD
-2.04 (-1.32%)
Updated May 8, 2024 04:00 PM ET
After-Market: $152.25 -0.04 (-0.03%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth B Momentum C VGM
Price, Consensus and EPS Surprise
ALNY 152.29 -2.04(-1.32%)
Will ALNY be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for ALNY based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ALNY
Alnylam (ALNY) Q1 Loss Narrower Than Expected, Sales Rise Y/Y
Compared to Estimates, Alnylam (ALNY) Q1 Earnings: A Look at Key Metrics
ALNY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Alnylam Pharmaceuticals (ALNY) Reports Q1 Loss, Tops Revenue Estimates
Annexon (ANNX) to Report Q1 Earnings: What's in the Cards?
Gear Up for Alnylam (ALNY) Q1 Earnings: Wall Street Estimates for Key Metrics
Other News for ALNY
Alnylam Issues 2023 Corporate Responsibility Report
Analysts Are Bullish on These Healthcare Stocks: Alnylam Pharma (ALNY), Crispr Therapeutics AG (CRSP)
Alnylam price target raised by $5 at H.C. Wainwright, here's why
Regeneron: Dissecting The First Quarter Results And Regulatory Setbacks
Alnylam Pharma (ALNY) Receives a Hold from Oppenheimer